Navigation Links
Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
Date:4/13/2009

NOVATO, Calif., April 13 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP) today announced the appointment of Patrice P. Rioux, M.D., Ph.D., as Chief Medical Officer ("CMO"). Dr. Rioux will be responsible for the clinical and regulatory advancement of Raptor's clinical-stage drug development programs.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071022/NYM074LOGO )

Raptor's clinical programs include Delayed-Release Cysteamine ("DR Cysteamine") for the potential treatment of nephropathic cystinosis ("cystinosis"), non-alcoholic steatohepatitis ("NASH") and Huntington's Disease ("Huntington's"), as well as Convivia(TM), for the potential treatment of aldehyde dehydrogenase ("ALDH2") deficiency.

Dr. Rioux has extensive experience as a clinician, researcher, medical director and regulatory specialist. Most recently, Dr. Rioux was CMO of FerroKin Biosciences, an early-stage developer of iron chelator for treatment of anemias. Prior to that, he was CMO and Vice President Clinical/Regulatory for Edison Pharmaceuticals, which focused on developing drugs to treat inherited and acquired energy impairment diseases. Dr. Rioux' three-decade career includes industry experience at companies such as Repligen Corp., Arrow International, Variagenics, Inc., Biogen and GRP (Groupement de Recherche en Pharmacologie). He previously was a researcher in Clinical Research and Epidemiology at INSERM (Institut National de la Sante et de la Recherche Medicale), a French organization that supports national research in the medical field, from 1975 to 1995. Educated in France, Dr. Rioux has an M.D., a Ph.D. in Mathematical Statisics, and a Masters in Pharmacology.

Christopher M. Starr, Ph.D.,
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
2. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
3. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
4. Raptor Pharmaceuticals Provides Update on Targeting Platforms
5. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
6. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
7. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
8. Raptor Pharmaceuticals Provides Update of Product Programs
9. Strativa Pharmaceuticals Provides Product Pipeline Update
10. Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
11. Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... HILL, Conn. , July 29, 2014 Numotion,s ... 2014, Mike Swinford will be the company,s new ... a highly successful 22-year career at GE where he worked ... million in annual revenue to over $5 billion. His most ... Global Services. "I am thrilled to join ...
(Date:7/29/2014)... Fla. , July 29, 2014 /PRNewswire-iReach/ -- ... service provider, has launched its Medical Equipment ...  These services are tailored to the cruise ... standards prompted industry operators to propose that they ... MHG Medical,s new program is intended to create ...
(Date:7/29/2014)... 29, 2014  Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Chemistry (AACC) 2014 Clinical Lab Expo today by unveiling ... ways Roche is partnering with customers to redefine the ... us every day that they,re looking for a partner ... their labs and offices," said Jack Phillips , ...
Breaking Medicine Technology:Numotion Names Mike Swinford CEO 2MHG Medical Management Services Aims to Change Cruise Industry Standard With New Equipment Maintenance Program 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 4
... Schering-Plough Corporation,(NYSE: SGP ) today reported that ... Phase II study of boceprevir, its investigational oral ... chronic,hepatitis C virus (HCV) genotype 1 were presented ... for the Study of the Liver (EASL). The,ongoing ...
... Into New Promising Drugs to Combat Hepatitis ... C ... Stem Cells of Potential Benefit in Liver Transplantation, ... At today,s sessions of the 43rd Annual Meeting of the European,Association for the ...
Cached Medicine Technology:Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 2Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 3Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 4Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 5Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 6Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 7Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 8Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 9Basic Science Discoveries Yield Progress in Hepatology 2Basic Science Discoveries Yield Progress in Hepatology 3Basic Science Discoveries Yield Progress in Hepatology 4
(Date:7/29/2014)... TUESDAY, July 29, 2014 (HealthDay News) --,The time at ... affect their chances for survival, new research suggests. ... weekends or during holidays is associated with a 13 ... business hours, researchers report. Every year, more than ... most severe type of heart attack, which is caused ...
(Date:7/29/2014)... July 29, 2014 (HealthDay News) -- Chlorine helps keep ... more likely to develop eye infections, doctors say. ... as well as blurry vision, said Dr. Sampson Davis, ... in New Jersey. It,s important to understand why ... washes away the outer film layer of the eye ...
(Date:7/29/2014)... 29, 2014 The Board of Governors of ... Hart LLP ’s Connie Akridge to serve as ... as President of the Foundation. Akridge served as President of ... a partner at Holland & Hart in Las Vegas, providing ... matters to insurance and healthcare clients for more than 25 ...
(Date:7/29/2014)... 2014 Tylenol lawsuits ( http://www.tylenollawsuitclaims.com/ ... suffered serious liver injuries due to the acetaminophen ... a multidistrict litigation underway in U.S. District Court, ... According to an Order dated July 23rd, the ... bellwether case and discovery issues. Among other things, ...
(Date:7/29/2014)... Dennis Thompson HealthDay Reporter ... healthy diet and good sleep can protect the body against ... process at a cellular level, researchers report. A study ... linked to increased shortening of telomeres, the protective caps at ... "We found that over a one-year period, the more ...
Breaking Medicine News(10 mins):Health News:Heart Attack Patients Treated at Night, Weekends May Have Worse Outcomes 2Health News:Protect Your Eyes When Hitting the Pool 2Health News:Holland & Hart LLP Attorney Connie Akridge Reappointed Trustee of the Nevada Bar Foundation 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:Healthy Habits May Slow Cellular Signs of Aging, Study Finds 2Health News:Healthy Habits May Slow Cellular Signs of Aging, Study Finds 3
... As the United States moves toward the goal of ... from the Regenstrief Institute provides a framework for evaluating the ... as the health internet. The study, which appears ... American Medical Informatics Association , also reports on the initial ...
... ... resource deployment through enhanced territory alignment , ... (PRWEB) May 11, 2010 -- The TerrAlign Group, Inc. a ... the inaugural launch of Veeva System’s Veeva Web™ program. Inclusion in this program ...
... So often the rare informs the common. Penn researchers ... have shown that it may be related to epileptic and ... A team of researchers from the University of Pennsylvania School ... professor of Neurology and director of the Penn Epilepsy Center, ...
... Oklahoma, Massachusetts asked to pull back products , TUESDAY, ... E.coli-tainted lettuce expanded late Monday as another food company ... farm currently under investigation by the U.S. Food and ... , According to the Associated Press , California-based ...
... Only ... ... KWizCom, a leading provider of critical SharePoint components to over 3,000 organizations around the ... giant AT&T. KWizCom’s Mobile Extensions , a smart phone connector that permits intelligent, ...
... Canvas Provides Health ... On Mobile Devices. , , ... Herndon, VA (PRWEB) May 11, 2010 -- Canvas announced today it had released ... HITECH compliant mobile applications on the Canvas service. The Health Insurance Portability and ...
Cached Medicine News:Health News:Measuring success: Regenstrief helps assess value of investment in health info tech 2Health News:TerrAlign Selected to Join Veeva System's Veeva Web Program 2Health News:TerrAlign Selected to Join Veeva System's Veeva Web Program 3Health News:TerrAlign Selected to Join Veeva System's Veeva Web Program 4Health News:Rare disease in Amish children sheds light on common neurological disorders 2Health News:Tainted Lettuce Recall Expands 2Health News:Tainted Lettuce Recall Expands 3Health News:KWizCom's Mobile Extensions for SharePoint Receive AT&T Certified Solutions Status 2Health News:HIPAA HITECH Compliant Mobile Apps Available for Android, Blackberry and Windows Mobile Smartphones 2Health News:HIPAA HITECH Compliant Mobile Apps Available for Android, Blackberry and Windows Mobile Smartphones 3Health News:HIPAA HITECH Compliant Mobile Apps Available for Android, Blackberry and Windows Mobile Smartphones 4
... Spatula Tips That Mimic Corneal Curvature. Designed To ... Created With The IntraLase TMFS Laser System., ... Of The Forceps Are Designed To Facilitate Access ... Achieved, The Cross-Action Forceps Design Allows The Surgeon ...
... Allowing The Exact,Outer Diameter Measurement Of A ... ,Increments.,Easy And Quick To Use, With One-HandedOperation. ... Over A Cornea For Confirmation Of Exact ... ,Guaranteed For ...
... Safely And Easily Cut Foldable Lenses Through ... The Incision., ,Specially Designed To Cut And ... Lenses With Ease With One Instrument., ,Ideal ... Lenses Which Are Damaged, The Wrong Diopter ...
... Gauge Measures 360 Degrees & Can Be ... A Cornea. 7mm Inner Diameter & 14mm Outer ... Only Astigmatism Gauge That Can Be Set For ... Degree Around The Globe., ,Marks Single Or Paired ...
Medicine Products: